Skip to Content



Our Densigen platform provides a versatile approach for the creation of immunomodulatory products promoting broad and robust T cell immunity against multiple indications including chronic infections and cancer. Densigen is a synthetic peptide immunotherapeutic platform that is designed to elicit T cell responses across multiple targets for a given disease. Densigen technology includes a fluorocarbon tail, a novel stabilizing feature that creates a depot upon administration and has the potential to lead to a strong and sustained activation of the immune system, even in subjects with established immunotolerance. Densigens also have the ability to elicit broad human leukocyte antigen (HLA) type-independent immune responses with the possibility that nearly all patients may benefit from Densigen immunotherapy regardless of the individual to individual differences in immune systems.